Other Clinical Trial - Pro-thrombotic Status in Patients With SARS-Cov-2

Status Active, not recruiting

Clinical Trial Summary

The present study is ideated to prospectively investigate in patients with severe acute respiratory syndrome (SARS) due to Coronavirus 19 (SARS-Cov-2) infection and moderate-severe respiratory failure the patterns and changes in platelet reactivity, thrombotic status and endothelial function. The observed patterns and changes will be related with inflammatory status, myocardial injury and outcomes

Clinical Trial Description

Preliminary evidences suggested that patients with SARS-Cov-2 infection and concomitant presence of cardiovascular risk factors (i.e. arterial hypertension) and/or cardiovascular history (i.e. prior myocardial infarction) are at poor prognosis. The first reports from China suggested in patients with SARS-Cov-2 infection a heightened inflammatory burden associated with significant changes in coagulative status (i.e. low platelet count, increased D-dimer) and dysfunction of micro-vessels in pulmonary circulation. No data are available about patterns and changes in platelet reactivity, activation of coagulation factors and endothelial function during SARS-Cov-2 infection. The present study is ideated to fill this gap. Patients with moderate to severe respiratory failure due to SARS-Cov-2 infection will be enrolled. One blood sample will be obtained from each patient at the early, mid and late stage of disease. Several markers of platelet, coagulation and endothelial function will be related with laboratory, clinical, electrocardiographic, imaging (transthoracic echocardiogram, pulmonary ultrasonography, computed tomography) and outcome data. To better describe typical patterns of disease regarding inflammation, platelet function and coagulation alteration, data from cases will be compared with control groups negative for SARS-CoV-2 infection, but with ST-segment elevation myocardial infarction or moderate-severe respiratory failure due to other agents. ;

Study Design

Related Conditions & MeSH terms

COVID-19
Severe Acute Respiratory Syndrome
Severe Acute Respiratory Syndrome Coronavirus 2

Clinical Trial Details

NCT number	NCT04343053
Study type	Interventional
Source	University Hospital of Ferrara
Contact
Status	Active, not recruiting
Phase	N/A
Start date	April 8, 2020
Completion date	November 12, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05543616` - A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children	Phase 2/Phase 3
Recruiting	`NCT04516811` - Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19	Phase 3
Completed	`NCT04334044` - Treatment of SARS Caused by COVID-19 With Ruxolitinib	Phase 1/Phase 2
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Recruiting	`NCT04466241` - Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial	Phase 2/Phase 3
Withdrawn	`NCT04381923` - COVIDNOCHE Trial (HFNO Versus CPAP Helmet) in COVID-19 Pneumonia	N/A
Recruiting	`NCT04402879` - CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals	N/A
Recruiting	`NCT04661631` - Surgery and Lung Ultrasound in COVID-19 Infection
Completed	`NCT04376476` - Host-pathogen Interactions During SARS-CoV-2 Infection	N/A
Completed	`NCT04375098` - Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection	Phase 2
Completed	`NCT04402060` - A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19	Phase 1/Phase 2
Active, not recruiting	`NCT04365101` - Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19	Phase 1/Phase 2
Completed	`NCT04354779` - Antibody Seroprevalence and Rate of Asymptomatic Infections With SARS-CoV-2 in Austrian Hospital Personnel.
Recruiting	`NCT04367207` - African Covid-19 Critical Care Outcomes Study
Terminated	`NCT04409873` - Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)	Phase 2
Completed	`NCT04602351` - Communication in ICU During COVID-19
Terminated	`NCT04707703` - Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis	Phase 3
Active, not recruiting	`NCT04987528` - Pulmonary Fibrosis During Severe COVID-19 Pneumonia
Completed	`NCT04667936` - Evaluation of Sedation in COVID-19 ARDS
Completed	`NCT04423770` - COVID-19 Related Health and Infection Control Practices Among Dentists

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Pro-thrombotic Status in Patients With SARS-Cov-2 Infection — ATTAC-Co

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms